Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature
- PMID: 17902149
- DOI: 10.1002/ppul.20693
Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature
Abstract
Mucoactive agents are used to treat a variety of lung diseases involving impaired mucociliary clearance or mucus hypersecretion. The mucoactive agents studied most frequently are N-acetylcysteine (NAC), recombinant human DNase (rhDNase), and hypertonic saline. Studies on the efficacy of these have been mainly conducted in adults, and in patients with cystic fibrosis (CF). The exact role of mucoactive agents in children with non-CF lung disease is not well established. We present an overview of the current literature reporting clinical outcome measures of treatment with NAC, rhDNase, and hypertonic saline in children.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.Respirology. 2017 Aug;22(6):1084-1092. doi: 10.1111/resp.13047. Epub 2017 Apr 11. Respirology. 2017. PMID: 28397992
-
Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.Am J Respir Crit Care Med. 2002 Aug 1;166(3):352-5. doi: 10.1164/rccm.2110015. Am J Respir Crit Care Med. 2002. PMID: 12153969 Clinical Trial.
-
Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.Am J Respir Crit Care Med. 1997 Jul;156(1):173-7. doi: 10.1164/ajrccm.156.1.9512074. Am J Respir Crit Care Med. 1997. PMID: 9230743 Clinical Trial.
-
The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?Curr Opin Pulm Med. 2014 Nov;20(6):601-6. doi: 10.1097/MCP.0000000000000104. Curr Opin Pulm Med. 2014. PMID: 25221855 Review.
-
Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.Lancet. 2001 Oct 20;358(9290):1316-21. doi: 10.1016/S0140-6736(01)06412-1. Lancet. 2001. PMID: 11684212 Clinical Trial.
Cited by
-
Dornase alpha inhalations as a treatment option for recurrent lower respiratory tract infections in a child with Sotos syndrome.Wien Klin Wochenschr. 2014 Jul;126(13-14):431-4. doi: 10.1007/s00508-014-0552-2. Epub 2014 Jun 5. Wien Klin Wochenschr. 2014. PMID: 24899541
-
Genetics, diagnosis, and future treatment strategies for primary ciliary dyskinesia.Expert Opin Orphan Drugs. 2015 Mar 1;3(1):31-44. doi: 10.1517/21678707.2015.989212. Epub 2014 Nov 29. Expert Opin Orphan Drugs. 2015. PMID: 26998415 Free PMC article.
-
Airway mucus function and dysfunction.N Engl J Med. 2010 Dec 2;363(23):2233-47. doi: 10.1056/NEJMra0910061. N Engl J Med. 2010. PMID: 21121836 Free PMC article. Review. No abstract available.
-
SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis.Thorax. 2014 Dec;69(12):1105-12. doi: 10.1136/thoraxjnl-2014-205953. Thorax. 2014. PMID: 25389139 Free PMC article. Clinical Trial.
-
How cations can assist DNase I in DNA binding and hydrolysis.PLoS Comput Biol. 2010 Nov 18;6(11):e1001000. doi: 10.1371/journal.pcbi.1001000. PLoS Comput Biol. 2010. PMID: 21124947 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical